For UK HealthTech companies
Your clinical evidence is strong, your economic case is losing NHS deals
NHS finance teams need quantified cost savings and return on investment, not clinical outcomes alone. Without a robust economic model, procurement decisions stall or go elsewhere, costing you contracts worth hundreds of thousands of pounds.
Two minutes. Solva follows up with specific pricing and value proposition options.
- Successful pilots failing to convert into long-term contracts.
- Difficulty articulating the financial return on investment (ROI) to NHS finance teams.
- Being stuck in 'pilot purgatory' with multiple trials but no scalable revenue.
- Pricing models that are not aligned with NHS budgeting structures or private healthcare purchasing power.
- Wasted resources on pilots that do not scale.
- Inefficient allocation of sales and marketing efforts.
- Missed revenue opportunities of hundreds of thousands of pounds per solution.
- Increased burn rate due to prolonged sales cycles.
- Delayed adoption of beneficial digital health solutions, impacting patient care.
- Limited access to innovative technologies for UK patients.
- Perception as a company that struggles with commercialisation.
- Reduced trust from potential NHS and private healthcare partners.
80% of healthcare AI projects fail to scale beyond the pilot phase across the NHS and private healthcare organisations (HealthTech Digital, 2025)
Frequently asked questions
Why does this problem persist?
Healthtech companies often focus heavily on clinical efficacy but neglect to build a robust economic case. NHS decision-makers operate under financial pressure and require clear evidence of cost savings or efficiency gains, which many startups fail to provide in a structured, procurement-friendly format.
What is the cost of leaving it unaddressed?
Suboptimal pricing and a weak value proposition can lead to missed contracts, reducing potential annual revenue by hundreds of thousands of pounds per solution (Standard Ledger, 2026)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.